Sofgen Pharma S.A (PROCF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Sofgen Pharma S.A $0.00, price $0.00, upside +0.0%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Sofgen Pharma S.A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Sofgen Pharma S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics.
Show more
Sofgen Pharma S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The company develops and manufactures Softgel and related technologies under the Softigel, Sofgen, Softcaps, and Funtrition brands; and Softgel pharmaceutical products, such as Advil, Apronax Liquidgels, multivitamins, Vitamin D, and Dolex ActivGel. It also formulates, manufactures, and markets branded prescription drugs in therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory; and manufactures and markets personal high-complexity drugs for hospital use comprising antibiotics, blood clot, immunosuppressant, oncology, and analgesics products. In addition, the company develops, manufactures, and markets OTC consumer healthcare products consisting of gastrointestinal, skin care, cough and cold, analgesics, urological, and vitamin, minerals, and supplements, as well as antibiotics, anti-infective, and anti-parasitic. Further, it offers blood glucose meters, telemonitoring, Rx oral anti-diabetics products, insulin delivery systems, and other diabetes solutions; and syringes, double chamber syringes, injection vials, injection ampoules, sterilized powder products, sterile droppers, and lyophilized solid vials. The company was formerly known as Procaps Group S.A. Sofgen Pharma S.A. was founded in 1977 and is based in Luxembourg, Luxembourg.
Stock analysis
Sofgen Pharma S.A (PROCF) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
How firm this estimate is: it rests on 6 models at a data quality of 87/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Sofgen Pharma S.A reported revenue of $374M in FY2024 versus $404M in FY2021, a compound −2.5%/yr. Reported net income was −$68.3M in FY2024.
Key figures
Market cap $58.4M · P/S ratio 0.16 · EPS (TTM) $−0.6800 · Net margin −18.3% · Return on assets (EBIT) 6.0% · Operating margin 11.1% · Revenue (TTM) $374M · Revenue growth (YoY) +7.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 0%, PROCF screens cheaper than that median.
Fair Value models
Bear $0.0001Fair Value $0.0001Bull $0.0001
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.15/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−11.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.5%
’21
’22
’23
’24
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.1% (2021) → −8.7% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside+0.0% · Above median
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−4.0% · Bottom 25%
Net margin (TTM)−18.3% · Bottom 25%
Operating margin (TTM)11.1% · Above median
Growth and dividend
Revenue growth7.3% · Above median
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)33· sector 17
FUTURE (revenue growth)37· sector 24
PAST (return on equity)0· sector 27
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 30
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Sofgen Pharma S.A (PROCF) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0001 versus the last price from Sep 25, 2026 of $0.0001, about +0% upside (fairly valued).
What is the fair value of PROCF?
Our model-based fair value for Sofgen Pharma S.A is $0.0001 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0001.
What is the quality score of PROCF?
Sofgen Pharma S.A has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sofgen Pharma S.A (PROCF)?
Our model-based price target is the fair value of $0.0001 (as of Sep 27, 2026) from 6 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Sofgen Pharma S.A stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus the last price from Sep 25, 2026 of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Sofgen Pharma S.A (PROCF)?
Sofgen Pharma S.A reported trailing-twelve-month revenue of about $374M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Sofgen Pharma S.A (PROCF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sofgen Pharma S.A it is $0.0001 per share (as of Sep 27, 2026), against a price of $0.0001. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is Sofgen Pharma S.A stock overvalued or undervalued in 2026?
As of Sep 27, 2026, PROCF trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PROCF?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For Sofgen Pharma S.A the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sofgen Pharma S.A worth?
The market values Sofgen Pharma S.A at about $58.4M (market capitalisation, as of Sep 27, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of Sofgen Pharma S.A (PROCF)?
Balance-sheet figures for Sofgen Pharma S.A (as of Sep 27, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
Which stocks are comparable to Sofgen Pharma S.A?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sofgen Pharma S.A stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 40/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PROCF calculated?
We run Sofgen Pharma S.A through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Sofgen Pharma S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sofgen Pharma S.A (PROCF)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sofgen Pharma S.A right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Sofgen Pharma S.A
How large is the market capitalisation of Sofgen Pharma S.A (PROCF)?
The market capitalisation of Sofgen Pharma S.A is $58.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sofgen Pharma S.A (PROCF)?
The price-to-sales ratio of Sofgen Pharma S.A is 0.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sofgen Pharma S.A (PROCF)?
Earnings per share at Sofgen Pharma S.A are $−0.6800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sofgen Pharma S.A (PROCF)?
The net margin of Sofgen Pharma S.A is −18.3% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Sofgen Pharma S.A (PROCF)?
On an EBIT basis the return on assets of Sofgen Pharma S.A is 6.0% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sofgen Pharma S.A (PROCF)?
The operating margin of Sofgen Pharma S.A is 11.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sofgen Pharma S.A (PROCF)?
Revenue at Sofgen Pharma S.A is growing +7.3% versus a year earlier (3y avg −2.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sofgen Pharma S.A (PROCF)?
Earnings per share at Sofgen Pharma S.A are growing −63.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sofgen Pharma S.A (PROCF) generate?
The free cash flow of Sofgen Pharma S.A is $63.4M (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sofgen Pharma S.A (PROCF) carry?
The net debt of Sofgen Pharma S.A is $276M (fiscal year 2024, ≈ 4.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sofgen Pharma S.A in the live analysis
One click puts Sofgen Pharma S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026